2022
TCT-164 Targeted Therapy With a Localized Abluminal Groove Low-Dose Sirolimus-Eluting Biodegradable-Polymer Coronary Stent: Subgroup Analysis of 5-Year Outcomes of the TARGET All Comers Randomized Trial
Kelbæk H, Lansky A, Xu B, Baumbach A, van Royen N, Knaapen P, Johnson T, Smits P, Vlachojannis G, Arkenbout K, Holmvang L, Janssens L, Ochala A, Wijns W. TCT-164 Targeted Therapy With a Localized Abluminal Groove Low-Dose Sirolimus-Eluting Biodegradable-Polymer Coronary Stent: Subgroup Analysis of 5-Year Outcomes of the TARGET All Comers Randomized Trial. Journal Of The American College Of Cardiology 2022, 80: b66. DOI: 10.1016/j.jacc.2022.08.193.Peer-Reviewed Original Research
2021
TCT-489 Three-Year Outcomes of Patients Treated With the Firehawk Stent Versus XIENCE Stent on the Basis of Diabetes Status: Subgroup Analysis of the TARGET All Comers Trial
Hussain Y, Wijns W, Xu B, Kelbæk H, Knaapen P, Zheng M, Slagboom T, Johnson T, Smits P, Arkenbout K, Holmvang L, Janssens L, Ochala A, Brugaletta S, Schmitz T, Anderson R, Rittger H, Berti S, Barbato E, Toth G, Maillard L, Valina C, Buszman P, Thiele H, Schachinger V, Baumbach A, Lansky A. TCT-489 Three-Year Outcomes of Patients Treated With the Firehawk Stent Versus XIENCE Stent on the Basis of Diabetes Status: Subgroup Analysis of the TARGET All Comers Trial. Journal Of The American College Of Cardiology 2021, 78: b200. DOI: 10.1016/j.jacc.2021.09.1342.Peer-Reviewed Original ResearchTCT-290 Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus: Results From the PIONEER III Clinical Trial
Thomas A, Kereiakes D, Leon M, Baumbach A, Windecker S, Pietras C, Dressler O, Issever M, Curtis M, Bertolet B, Zidar J, Smits P, Diaz V, Mclaurin B, Cequier A, Takahashi A, Amoroso G, Kakuta T, Carney R, Saito S, Lansky A. TCT-290 Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus: Results From the PIONEER III Clinical Trial. Journal Of The American College Of Cardiology 2021, 78: b119. DOI: 10.1016/j.jacc.2021.09.1143.Peer-Reviewed Original Research
2020
The Firehawk Stent: A Review of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent.
Saito Y, Grubman D, Cristea E, Lansky A. The Firehawk Stent: A Review of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent. Cardiology In Review 2020, 28: 208-212. PMID: 32032131, DOI: 10.1097/crd.0000000000000298.Peer-Reviewed Original ResearchConceptsAbluminal grooveFIREHAWK stentBiodegradable Polymer Sirolimus-Eluting StentLate adverse eventsPercutaneous coronary interventionCurrent clinical evidenceSirolimus-Eluting StentsDrug-eluting stent technologyAdverse eventsCoronary interventionClinical outcomesChronic inflammationClinical evidenceHypersensitivity reactionsRecent trialsDrug concentrationsStent technologyStentsInflammationFIREHAWKReviewSirolimus
2019
TCT-287 Impact of Eligibility Criteria on Clinical Outcomes of Firehawk and XIENCE Coronary Drug-Eluting Stent in an All-Comers Randomized Trial
Saito Y, Wijns W, Baumbach A, Xu B, Kelbæk H, van Royen N, Zheng M, Knaapen P, Slagboom T, Johnson T, Vlachojannis G, Holmvang L, Janssens L, Ochala A, Brugaletta S, Anderson R, Rittger H, Berti S, Barbato E, Toth G, Maillard L, Valina C, Buszman P, Thiele H, Lansky A. TCT-287 Impact of Eligibility Criteria on Clinical Outcomes of Firehawk and XIENCE Coronary Drug-Eluting Stent in an All-Comers Randomized Trial. Journal Of The American College Of Cardiology 2019, 74: b286. DOI: 10.1016/j.jacc.2019.08.361.Peer-Reviewed Original Research
2018
TCT-132 Balloon-Expandable ePTFE-Covered Stent for Obstructive Lesions in the Iliac Artery: 24-Month Results from the BOLSTER Trial
Bouras G, Laird J, Zeller T, Holden A, Zhou S, Mena-Hurtado C, Cristea E, Lansky A, Lansky A. TCT-132 Balloon-Expandable ePTFE-Covered Stent for Obstructive Lesions in the Iliac Artery: 24-Month Results from the BOLSTER Trial. Journal Of The American College Of Cardiology 2018, 72: b57. DOI: 10.1016/j.jacc.2018.08.1238.Peer-Reviewed Original Research
2017
CRT-700.07 Nine-Month RESULTS Of The BIOHELIX-I Clinical Trial Study: Evaluation Of The PRO-Kinetic Energy Cobalt Chromium Bare-Metal Stent
Michael T, Richardt G, Lansky A, Carney R, Khan M, Shehadeh A, Zeymer U, Gupta S. CRT-700.07 Nine-Month RESULTS Of The BIOHELIX-I Clinical Trial Study: Evaluation Of The PRO-Kinetic Energy Cobalt Chromium Bare-Metal Stent. JACC Cardiovascular Interventions 2017, 10: s59. DOI: 10.1016/j.jcin.2016.12.202.Peer-Reviewed Original Research
2016
CRT-200.54 Evaluation of 2-year Clinical Outcomes From Post-market Trials With Everolimus-eluting Cobalt Chromium Stents in Diabetics
Ng V, Seth A, Alkhalil I, Grube E, Morice M, Mao V, Deible R, Sudhir K, Lansky A. CRT-200.54 Evaluation of 2-year Clinical Outcomes From Post-market Trials With Everolimus-eluting Cobalt Chromium Stents in Diabetics. JACC Cardiovascular Interventions 2016, 9: s20. DOI: 10.1016/j.jcin.2015.12.086.Peer-Reviewed Original Research
2015
Will this trial change my practice? The Dual Antiplatelet Therapy (DAPT) study - 12 or 30 months of dual antiplatelet therapy after drug-eluting stents.
Grundeken MJ, Lansky A, Tanguay JF, Gershlick A, Baumbach A, Cuisset T. Will this trial change my practice? The Dual Antiplatelet Therapy (DAPT) study - 12 or 30 months of dual antiplatelet therapy after drug-eluting stents. EuroIntervention 2015, 11: 364-5. PMID: 26196757, DOI: 10.4244/eijv11i3a71.Peer-Reviewed Original Research
2014
TCT-605 Safety and Efficacy of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Lesions: 2-Year Results from the Prospectively Patient-Level Pooled Analysis of the TARGET I and TARGET II Trials
Zhao Y, Xu B, Yang Y, Zhang R, Changsheng M, Li H, Huo Y, Lansky A, Leon M, Gao R. TCT-605 Safety and Efficacy of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Lesions: 2-Year Results from the Prospectively Patient-Level Pooled Analysis of the TARGET I and TARGET II Trials. Journal Of The American College Of Cardiology 2014, 64: b176-b177. DOI: 10.1016/j.jacc.2014.07.670.Peer-Reviewed Original ResearchTCT-597 Three Year Clinical Outcomes of a Unique Sirolimus-Eluting Stent with Fully Absorbable Polymer Coating: Long-term Results from the DESSOLVE I and the DESSOLVE II Clinical Trials
Ormiston J, Lansky A, Donohoe D, Knape C, Vrolix M, Verheye S, Schoors D, Wijns W. TCT-597 Three Year Clinical Outcomes of a Unique Sirolimus-Eluting Stent with Fully Absorbable Polymer Coating: Long-term Results from the DESSOLVE I and the DESSOLVE II Clinical Trials. Journal Of The American College Of Cardiology 2014, 64: b174. DOI: 10.1016/j.jacc.2014.07.661.Peer-Reviewed Original ResearchCritical evaluation of stents in the peripheral arterial disease of the superficial femoral artery – focus on the paclitaxel eluting stent
Litsky J, Chanda A, Stilp E, Lansky A, Mena C. Critical evaluation of stents in the peripheral arterial disease of the superficial femoral artery – focus on the paclitaxel eluting stent. Medical Devices Evidence And Research 2014, Volume 7: 149-156. PMID: 24920940, PMCID: PMC4045256, DOI: 10.2147/mder.s45472.Peer-Reviewed Original ResearchSuperficial femoral arteryPeripheral arterial diseaseArterial diseaseSymptomatic peripheral arterial diseasePercutaneous transluminal balloon angioplastyPreferred initial therapyTransluminal balloon angioplastySelf-expanding nitinol stentsInitial therapyObstructive lesionsSFA diseaseEndovascular managementObstructive diseaseEndovascular treatmentAdequate therapyBalloon angioplastySFA stenosisFemoral arteryDurable resultsClinical practiceLong occlusionsDiseaseNitinol stentsStentsBiomechanical forces
2013
TCT-20 Two-Year Clinical Follow-Up of the FIREHAWK Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent in the Treatment of Patients with De Novo Native Coronary Artery Lesions: The TARGET I Trial
Xu B, Gao R, Lansky A, Yang Y, Changsheng M, Han Y, Chen S, Li H, Zhang R, Fu G, Yuan Z, Huo Y, Li W, Zhao Y, Leon M. TCT-20 Two-Year Clinical Follow-Up of the FIREHAWK Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent in the Treatment of Patients with De Novo Native Coronary Artery Lesions: The TARGET I Trial. Journal Of The American College Of Cardiology 2013, 62: b7-b8. DOI: 10.1016/j.jacc.2013.08.748.Peer-Reviewed Original ResearchDe novo native coronary artery lesionsBiodegradable Polymer Sirolimus-Eluting StentNovo native coronary artery lesionsNative coronary artery lesionsCoronary artery lesionsSirolimus-Eluting StentsTreatment of patientsTwo-Year ClinicalAbluminal grooveArtery lesionsI trialPatientsClinicalLesionsStentsTrialsTCT-181 Safety and Efficacy of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Lesions: 12-Month Results from the Prospectively Patient-Level Pooled Analysis of the TARGET I and TARGET II Trials
Gao R, Xu B, Lansky A, Yang Y, Zhang R, Changsheng M, Li H, Chen S, Han Y, Yuan Z, Huo Y, Li W, Zhao Y, Leon M. TCT-181 Safety and Efficacy of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Lesions: 12-Month Results from the Prospectively Patient-Level Pooled Analysis of the TARGET I and TARGET II Trials. Journal Of The American College Of Cardiology 2013, 62: b59. DOI: 10.1016/j.jacc.2013.08.915.Peer-Reviewed Original Research
2012
The Generations of Drug-Eluting Stents and Outcomes in Women
Ng VG, Lansky AJ. The Generations of Drug-Eluting Stents and Outcomes in Women. Interventional Cardiology Clinics 2012, 1: 183-195. PMID: 28582092, DOI: 10.1016/j.iccl.2012.01.002.Peer-Reviewed Original ResearchDrug-eluting stentsPercutaneous coronary artery revascularizationObstructive coronary artery diseaseCoronary artery revascularizationMinority of patientsCoronary artery diseaseCause of deathDrug-eluting stent technologyDrug eluting stentsArtery revascularizationArtery diseaseClinical trialsCardiovascular diseaseAntiproliferative drugsStentsStent technologyWomenStent platformsDiseaseOutcomesRevascularizationPatientsMainstayPrevalenceTrials
2011
FIVE-YEAR FOLLOW-UP OF POLYTETRAFLUOROETHYLENE-COVERED STENTS COMPARED WITH BARE METAL STENTS IN AORTOCORONARY SAPHENOUS VEIN GRAFTS: THE RANDOMIZED BARRICADE TRIAL
Genereux P, Goldberg S, O'Shaughnessy C, Midei M, Siegel R, Mintz G, Cristea E, Dangas G, Lansky A, Mehran R, Stone G. FIVE-YEAR FOLLOW-UP OF POLYTETRAFLUOROETHYLENE-COVERED STENTS COMPARED WITH BARE METAL STENTS IN AORTOCORONARY SAPHENOUS VEIN GRAFTS: THE RANDOMIZED BARRICADE TRIAL. Journal Of The American College Of Cardiology 2011, 57: e1621. DOI: 10.1016/s0735-1097(11)61621-5.Peer-Reviewed Original Research
2010
Clinical Follow-Up 3 Years After Everolimus- and Paclitaxel-Eluting Stents A Pooled Analysis From the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials
Caixeta A, Lansky AJ, Serruys PW, Hermiller JB, Ruygrok P, Onuma Y, Gordon P, Yaqub M, Miquel-Hebert K, Veldhof S, Sood P, Su X, Jonnavithula L, Sudhir K, Stone GW, Investigators S. Clinical Follow-Up 3 Years After Everolimus- and Paclitaxel-Eluting Stents A Pooled Analysis From the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials. JACC Cardiovascular Interventions 2010, 3: 1220-1228. PMID: 21232715, DOI: 10.1016/j.jcin.2010.07.017.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, Balloon, CoronaryAntineoplastic Agents, PhytogenicAspirinClopidogrelConfidence IntervalsCoronary Artery DiseaseDrug-Eluting StentsEverolimusFemaleFollow-Up StudiesHumansImmunosuppressive AgentsKaplan-Meier EstimateLogistic ModelsMaleMiddle AgedPaclitaxelPlatelet Aggregation InhibitorsProportional Hazards ModelsRandomized Controlled Trials as TopicRiskRisk Reduction BehaviorSirolimusTiclopidineTime FactorsConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsAdverse cardiac eventsTarget vessel failureCardiac eventsMyocardial infarctionSPIRIT IIProbable stent thrombosisAcademic Research ConsortiumEverolimus-eluting stentsVessel failureSignificant reductionLesion revascularizationPES patientsRevascularization eventsIII trialsClinical outcomesEE patientsStent thrombosisPooled analysisCumulative ratePersistent reductionSPIRIT IIIPatientsStentsComparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial.
Applegate RJ, Hermiller JJ, Sanz M, Doostzadeh J, Pierson W, Su X, Lansky AJ, Sudhir K, Stone GW. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial. EuroIntervention 2010, 6: 437-46. PMID: 20884430, DOI: 10.4244/eij30v6i4a75.Peer-Reviewed Original ResearchConceptsPaclitaxel-eluting stentsClinical outcomesStent typeMajor adverse cardiac eventsTwo-year event ratesSPIRIT IIIPaclitaxel-eluting coronary stentsSPIRIT III trialYear clinical outcomesAdverse cardiac eventsCardiac eventsIII trialsPE groupTwo-vesselPatientsEvent ratesCoronary stentsTrialsVessel treatmentStentsOutcomesVesselsSignificant interactionStentingLesionsIntravascular Ultrasound Findings of Stent Fractures in Patients With Sirolimus- and Paclitaxel-Eluting Stents
Doi H, Maehara A, Mintz GS, Tsujita K, Kubo T, Castellanos C, Lansky AJ, Witzenbichler B, Guagliumi G, Brodie B, Kellett MA, Parise H, Mehran R, Leon MB, Moses JW, Stone GW. Intravascular Ultrasound Findings of Stent Fractures in Patients With Sirolimus- and Paclitaxel-Eluting Stents. The American Journal Of Cardiology 2010, 106: 952-957. PMID: 20854956, DOI: 10.1016/j.amjcard.2010.05.024.Peer-Reviewed Original ResearchConceptsPaclitaxel-eluting stentsIntravascular ultrasound findingsSirolimus-eluting stentsUltrasound findingsStent fractureExternal elastic membrane areaClinical trial cohortSimilar frequencyComplete stent fracturePE fractureTrial cohortInstitutional cohortIVUS findingsStent lengthDistal fragmentIVUS featuresIVUS analysisCalcified plaquesStent fragmentsPatientsStrut fractureStentsMalalignmentCohortFracturesEverolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease
Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ. Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease. New England Journal Of Medicine 2010, 362: 1663-1674. PMID: 20445180, DOI: 10.1056/nejmoa0910496.Peer-Reviewed Original ResearchConceptsPaclitaxel-eluting stentsTarget lesion failureEverolimus-eluting stentsMajor secondary end pointPrimary end pointSecondary end pointsEnd pointMyocardial infarctionIschemia-driven target lesion revascularizationRoutine follow-up angiographyTarget vessel myocardial infarctionComposite rateTarget lesion revascularizationClinical end pointsCoronary artery diseaseSubgroup of patientsFollow-up angiographyEverolimus-ElutingAngiographic findingsPrespecified subgroupsArtery diseaseCardiac deathStent thrombosisPatientsStents